Independent Analyses To Inform Go/No-go Decisions
Publié le
Our client in this case was an investment organization specialized in biotechnology companies, and they required an urgent analysis of…
Publié le
Our client in this case was an investment organization specialized in biotechnology companies, and they required an urgent analysis of…
Publié le
Assessment of Clinical Validity of Circulating Tumor Cells (CTC) Quantification Clinical Validity Of Circulating Tumor Cells (CTC) In Patients With…
Publié le
Phase II study conducted with a dose-escalation minimization A phase II ophthalmology study was conducted with a dose-escalation minimization to…
Publié le
Biostatistical Expertise For Developing New Biomarkers And Diagnostic Tests IDDI has a long-term collaboration with a Sponsor to provide biostatistical…
Publié le
A Bayesian Study Design For Seamless Transition Between Phase II And Phase III Data collected by a sponsor suggested a…
Publié le
A Flexible Study Design with Randomization to Placebo The maximum tolerated dose of a new drug, supposed to alleviate some…
Publié le
New prognostic biomarkers for breast cancer: A range of biological markers were analyzed by polymerase chain reaction and immunohistochemistry in…
Publié le
In this meta-analysis, tumor responses and survival were analyzed combining the data from the different trials using patient individual data. The…
Publié le
Data Safety Monitoring Formal data safety monitoring, often performed by independent committees of physicians, biostatisticians and ethicists, has become common…
Publié le
A 70-genetic signature was shown in a single institution to have prognostic value in patients with node-negative breast cancer. The…